Should I buy or sell Benitec Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BNTC shares. View BNTC analyst ratings or view top-rated stocks .

What is Benitec Biopharma's stock price target for 2024?

1 analysts have issued 1 year target prices for Benitec Biopharma's shares. Their BNTC share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price. View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts .

How have BNTC shares performed in 2024?

Benitec Biopharma's stock was trading at $3.23 at the beginning of 2024. Since then, BNTC stock has increased by 118.9% and is now trading at $7.07. View the best growth stocks for 2024 here .

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,000 shares, an increase of 115.7% from the March 15th total of 5,100 shares. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.5% of the shares of the stock are short sold. View Benitec Biopharma's Short Interest .

When is Benitec Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BNTC earnings forecast .

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) announced its quarterly earnings results on Tuesday, February, 13th. The biotechnology company reported ($2.64) EPS for the quarter.

When did Benitec Biopharma's stock split?

Benitec Biopharma shares reverse split before market open on Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN) , Pfizer (PFE) , Amicus Therapeutics (FOLD) , Sorrento Therapeutics (SRNE) , Arbutus Biopharma (ABUS) , Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Anavex Life Sciences (AVXL) , BioLineRx (BLRX) and CRISPR Therapeutics (CRSP) .

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free BNTC Stock Alerts

$7.00

+0.18 (+2.64%)

(As of 01:39 PM ET)

Compare

Today's Range: $6.43
▼
$7.09
50-Day Range: $2.80
▼
$6.82
52-Week Range: $1.86
▼
$9.01

Volume: 170,364 shs
Average Volume: 66,041 shs
Market Capitalization: $18.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Benitec Biopharma alerts:

Benitec Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 41.4% Upside
$10.00 Price Target
Short Interest: Healthy
0.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.14
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

698th out of 918 stocks

Pharmaceutical Preparations Industry

314th out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
Benitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Benitec Biopharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.47% of the float of Benitec Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Benitec Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Benitec Biopharma has recently increased by 115.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Benitec Biopharma does not currently pay a dividend.
Dividend Growth
Benitec Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNTC.

2.3

News and Social Media Coverage

News Sentiment
Benitec Biopharma has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Benitec Biopharma this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for BNTC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Benitec Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Benitec Biopharma is held by insiders.
Percentage Held by Institutions
52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Benitec Biopharma has a P/B Ratio of 58.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Benitec Biopharma Stock (NASDAQ:BNTC)

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BNTC Stock News Headlines

April 18, 2024 | msn.com

Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?

April 18, 2024 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 18, 2024 | msn.com

Benitec Biopharma jumps 33% on $40M private financing

April 18, 2024 | markets.businessinsider.com

Why Benitec Biopharma Is Rising In Pre-market?

April 18, 2024 | globenewswire.com

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

April 18, 2024 | globenewswire.com

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

April 9, 2024 | finance.yahoo.com

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 24, 2024 | insidermonkey.com

11 Best ASX Stocks To Buy Now

February 25, 2024 | msn.com

Benitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20

February 13, 2024 | finance.yahoo.com

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

November 30, 2023 | finance.yahoo.com

Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns

November 30, 2023 | finance.yahoo.com

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

November 19, 2023 | morningstar.com

Benitec Biopharma Inc BNTC

November 17, 2023 | finance.yahoo.com

Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

November 15, 2023 | finanznachrichten.de

Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

November 14, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Benitec Biopharma (BNTC), Rezolute (RZLT)

November 13, 2023 | finance.yahoo.com

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

September 27, 2023 | msn.com

JMP Securities Maintains Benitec Biopharma (BNTC) Market Outperform Recommendation

September 26, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)

September 21, 2023 | finance.yahoo.com

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

August 21, 2023 | finance.yahoo.com

Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc

August 11, 2023 | finance.yahoo.com

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

August 9, 2023 | msn.com

Benitec Biopharma prices $30M equity offering

August 9, 2023 | finance.yahoo.com

Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

August 2, 2023 | msn.com

Benitec Biopharma (BNTC) Price Target Increased by 1600.00% to 69.36

See More Headlines

Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BNTC
CUSIP: N/A
CIK: 1808898
Web: www.benitec.com
Phone: 510-780-0819
Fax: 61 (0)3 9966-9923
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +46.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,560,000.00
Net Margins: N/A
Pretax Margin: -35,754.10%
Return on Equity: -204.34%
Return on Assets: -142.81%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 3.62
Quick Ratio: 3.62

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 220.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.12 per share
Price / Book: 56.83

Miscellaneous

Outstanding Shares: 2,590,000
Free Float: 2,481,000
Market Cap: $17.66 million
Optionable: No Data
Beta: 1.03

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Jerel A. Banks M.D. (Age 49)
Ph.D., Executive Chairman & CEO
Comp: $848.07k
Ms. Megan Joan Boston BComm (Age 52)
CA, Dip., GAICD, Executive Director
Comp: $439.17k
Dr. Michael Graham
Head of Discovery & Founding Scientist
Dr. Claudia Kloth
Senior Vice President of Manufacturing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BNTC Stock Analysis - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings or view top-rated stocks.
What is Benitec Biopharma's stock price target for 2024?: 1 analysts have issued 1 year target prices for Benitec Biopharma's shares. Their BNTC share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price.
View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts.
How have BNTC shares performed in 2024?: Benitec Biopharma's stock was trading at $3.23 at the beginning of 2024. Since then, BNTC stock has increased by 118.9% and is now trading at $7.07.
View the best growth stocks for 2024 here.
Are investors shorting Benitec Biopharma?: Benitec Biopharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,000 shares, an increase of 115.7% from the March 15th total of 5,100 shares. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.5% of the shares of the stock are short sold.
View Benitec Biopharma's Short Interest.
When is Benitec Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our BNTC earnings forecast.
How were Benitec Biopharma's earnings last quarter?: Benitec Biopharma Inc. (NASDAQ:BNTC) announced its quarterly earnings results on Tuesday, February, 13th. The biotechnology company reported ($2.64) EPS for the quarter.

When did Benitec Biopharma's stock split?: Benitec Biopharma shares reverse split before market open on Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.
What other stocks do shareholders of Benitec Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).
When did Benitec Biopharma IPO?: Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.
How do I buy shares of Benitec Biopharma?: Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNTC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Benitec Biopharma (BNTC) Stock Price, News & Analysis

Benitec Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Benitec Biopharma Stock (NASDAQ:BNTC)

BNTC Stock Price History

BNTC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

BNTC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™